Amedisys (NASDAQ:AMED) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Amedisys (NASDAQ:AMED – Free Report) in a research report released on Monday. The brokerage issued a buy rating on the health services provider’s stock. Several other equities analysts have also recently weighed in on AMED. TD Cowen increased their price target on Amedisys from $84.00 to $101.00 and gave […]
More Stories
World News in Brief: Mpox update, Haiti displacement, deadly strikes in Ukraine, Pakistan attack condemned
The mpox outbreak continues to constitute a public health emergency of international concern, the World Health Organization (WHO) said in...
Matt Gaetz Says He’s Not Returning to Congress Next Year
By Jack Phillips Former Florida Congressman Matt Gaetz on Friday responded to speculation that he could return to the U.S....
Economic Optimism Rises as Business Activity Soars to 31-Month High
By Tom Ozimek Business activity in the United States surged in November to its highest level in nearly three years,...
Children and amputees bear brunt of Myanmar’s deadly landmine epidemic
Myanmar has become the world’s deadliest country for landmine and unexploded ordnance casualties, with over 1,000 victims in 2023 alone,...
Integrated Investment Consultants LLC Acquires Shares of 1,840 The Trade Desk, Inc. (NASDAQ:TTD)
Integrated Investment Consultants LLC bought a new position in The Trade Desk, Inc. (NASDAQ:TTD – Free Report) during the third...
Navellier & Associates Inc. Purchases New Position in Fortinet, Inc. (NASDAQ:FTNT)
Navellier & Associates Inc. bought a new stake in shares of Fortinet, Inc. (NASDAQ:FTNT – Free Report) during the 3rd...